The Latest
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Pfizer’s deal with Innovent is the sixth partnership involving China-originated drugs since last July that involves at least $8 billion in total proceeds, according to BioPharma Dive data.
Updated 15 hours ago -
Permission granted by Thermo Fisher Scientific
Sponsored by Thermo Fisher ScientificProcess intensification: Separating fact from fiction
Uncover four key misconceptions that could be holding your intensification strategies back — and how to set your initiatives up for success.
-
Courtesy of Eli Lilly
Obesity drugsCVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
-
Permission granted by SR One
Q&A // China competitionSR One’s Simeon George on how China is rewriting biotech’s venture playbook
The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and steering dollars away from “half-baked ideas.”
-
Getty Images
Obesity drugsKailera’s three-pronged obesity shot shows promise in early trial
As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.
-
Permission granted by Verge Genomics
Emerging biotechVerge, following trial failure, rebrands its AI drug discovery ambitions
Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.
-
Getty Images
IPO windowCardio drugmaker Kardigan plans to go public
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
RA Capital Management is investing $30 million in Secretome Therapeutics, a company developing a new kind of cell therapy for the heart muscle weakness associated with Duchenne muscular dystrophy.
Updated May 28, 2026 -
Getty Images
VaccinesLilly dives into vaccine research with 3 biotech buyouts
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.
-
Getty Images
Apogee eczema drugs gets Blackstone backing, heads to Phase 3
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.
-
Sarah Silbiger via Getty Images
FDA delays decision on AstraZeneca breast cancer pill
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.
-
"Eli Lilly Corporate Center, Indianapolis, Indiana, USA" by Momoneymoproblemz is licensed under CC BY-SA 4.0
Gene editingEarly data for heart drug affirm Lilly’s billion-dollar bet on Verve
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
-
Getty Images
News roundupAstellas eyes more cost cuts; FDA panel to debate Moderna vaccine
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
-
Permission granted by Bristol Myers Squibb
Q&A // Brain drug revivalIn Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Kardigan, a startup run by former MyoKardia executives, outlined an offering that would support development of heart drugs licensed from Bristol Myers, Sanofi and Ionis Pharmaceuticals.
Updated May 27, 2026 -
Scott Olson via Getty Images
Obesity drugsLilly’s triple-acting obesity drug hits goal in Phase 3 trial
Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.
-
Getty Images
Parkinson’s drug from Biogen, Denali comes up short
High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
Updated May 22, 2026 -
Michael M. Santiago via Getty Images
RA Capital banks $75M for a biotech SPAC
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
-
Permission granted by Bristol-Myers Squibb
Bristol Myers deepens AI investment with Anthropic deal
The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.
-
Permission granted by Parabilis
IPO windowAfter raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
-
Getty Images
BioMarin notches win in study that could expand use of top-selling medicine
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
-
Vadym Plysiuk via Getty Images
Startup launchesOorja, run by Acceleron veterans, launches to make new fibrosis drugs
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
-
Scott Olson via Getty Images
Lilly snaps up Engage to advance non-viral genetic medicines
The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.
-
Getty Images
News roundup
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
-
Spencer Platt via Getty Images
A migraine drugmaker heads to the public markets through reverse merger
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
-
SpiffyJ via Getty Images
Relay drug shows early promise against rare blood vessel diseases
While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
